PMGC Holdings Inc. (ELAB) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists.
Analysis Summary
Trailing-twelve-month margins: gross margin 10.3%, operating margin -477.0%, net margin -5.2%.
At the current price of $4.77, ELAB has negative trailing earnings (P/E not meaningful) and an ROE of -98.35%. Market capitalisation stands at $2M.
Balance sheet quality for ELAB: current ratio of 1.7, net cash position of $2.8M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $4.77 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.14 |
| EV / EBITDA | -0.02 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -98.35% |
| Return on Invested Capital | -70.17% |
| Return on Assets | -59.90% |
| Gross Margin | 10.31% |
| Operating Margin | -477.02% |
| Net Margin | -522.97% |
Financial Health
| Debt / Equity | 0.83 |
| Current Ratio | 1.36 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ELAB | PMGC Holdings Inc. | $2M | 0.14 | -98.4% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -42.53% |
| 3 months | -65.68% |
| Year-to-date | -99.66% |
| 1 year | -99.91% |
52-Week Range
| 52-week High | $10684.80 |
| 52-week Low | $4.40 |
| Avg Volume (90d) | 221K |
Related companies: ATXI · BCTXZ · DRMA · MLEC · NCEL · NKGN · PBM
Explore sector: Healthcare · Biotechnology
More sections of ELAB: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks